Ruxolitinib versus best available therapy for PV intolerant or resistant to hydroxycarbamide in a randomized trial

Data from the randomized phase II MAJIC-PV trial, presented during the 2022 American Society of Hematology Annual Meeting, show that ruxolitinib—compared with best available therapy—significantly improved thrombosis-free survival (HR 0.56, 95% CI 0.32, 1.00, p=0.05) among patients with high-risk polycythemia vera that is resistant/intolerant to hydroxycarbamide. Patients attaining complete response within 1 year (HR 0.41, 95% CI 0.21, 0.78, p=0.01) and those on ruxolitinib (HR 0.58, 95% 0.35, 0.94, p=0.03) also had superior event-free survival.